PURA Confirms Cannabis Cultivation Deal With PAOG For Tomorrow
2020年7月27日 - 11:30PM
InvestorsHub NewsWire
Dallas, TX -- July 27, 2020 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today confirmed the cannabis cultivation deal with PAO
Group, Inc. (USOTC:
PAOG) is expected to close tomorrow, July 28, 2020. PAOG
Group is acquiring PURA’s cannabis cultivation operation in
exchange for PAOG common stock. The PAOG stock issued to PURA
is to be issued to PURA shareholders in a dividend
distribution. The target dividend ratio is for each PURA
shareholder to receive one share of PAOG stock for each share of
PURA held.
PAOG also intends to acquire NCM Biotech
from Kali-Extracts, Inc. (KALY).
NCM
Biotech is focused on medical research and the development of
treatments derived from its patented cannabis extraction
process.
NCM Biotech has
patented cannabis extraction operation which is focused on medical
research and the development of treatments derived from its
patented cannabis extraction process. See a recent research report
on CBD extracts derived from NCM Biotech's patented extraction
process: Journal of
Cannabis Research.
PURA’s cannabis
cultivation operation is thriving, has revenue, and has recently
purchased and relocated to a new property from its former leased
property. Texas lawmakers have recently implemented hemp
friendly farming regulations and in so doing, universities within
the State of Texas have initiated hemp farming research
programs. PURA's cannabis cultivation spinoff has initiated a
number of joint research applications
with Texas universities.
PURA had
previously spun-off its cannabis cultivation operation to Nouveau
(USOTC:
NOUV) and is now unwinding that deal to move forward with
PAOG.
For more
information on Puration, visit https://www.purationinc.com
Disclaimer/Safe
Harbor:
This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
過去 株価チャート
から 11 2024 まで 12 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Nouveau Life Pharmaceuticals Inc (PK) (その他OTC): 0 recent articles
その他のNouveau Life Pharmaceuticals Inc (PK)ニュース記事